Panacea Acquisition II (Panacea Acquisition II) EBITDA Margin % : 0.00% (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Panacea Acquisition II EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Panacea Acquisition II's EBITDA for the three months ended in Dec. 2022 was $-0.22 Mil. Panacea Acquisition II's Revenue for the three months ended in Dec. 2022 was $0.00 Mil. Therefore, Panacea Acquisition II's EBITDA margin for the quarter that ended in Dec. 2022 was 0.00%.

Panacea Acquisition II EBITDA Margin % Historical Data

The historical data trend for Panacea Acquisition II's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Acquisition II EBITDA Margin % Chart

Panacea Acquisition II Annual Data

Trend

Dec21

Dec22

EBITDA Margin %

Panacea Acquisition II Quarterly Data
	Jan21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EBITDA Margin %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Panacea Acquisition II's EBITDA Margin %

For the Shell Companies subindustry, Panacea Acquisition II's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panacea Acquisition II's EBITDA Margin % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Panacea Acquisition II's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Panacea Acquisition II's EBITDA Margin % falls into.

Panacea Acquisition II EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Panacea Acquisition II's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-0.975	/	0
	=	%

Panacea Acquisition II's EBITDA Margin % for the quarter that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	-0.221	/	0
	=	%

Panacea Acquisition II (NAS:PANA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Panacea Acquisition II EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Panacea Acquisition II's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Panacea Acquisition II (Panacea Acquisition II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

357 Tehama Street, Floor 3, San Francisco, CA, USA, 94103

Website

Panacea Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Executives

Ecor1 Capital Fund Qualified, L.p.	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p.	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Venture Opportunity Fund, Lp	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc	director, 10 percent owner	1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Panacea Holdings Ii, Llc	director, 10 percent owner	357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Douglas E Williams	director	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Douglas E. Giordano	director	C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017
Nina S Kjellson	director	C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Praveen P. Tipirneni	director	C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Sarah Marriott	director, officer: Secretary	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Perlen	officer: Chief Financial Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Caroline Stout	officer: Chief Investment Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Platshon	officer: Chief Operating Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103